mRCC stage migration: implications for trial design and analysis


    loading  Checking for direct PDF access through Ovid

Abstract

Tumor stage distribution in the population of patients with metastatic renal cell carcinoma (mRCC) enrolled in first-line clinical trials has changed over time, with a significant shift of patients to more-favorable risk groups. This phenomenon might result in difficulty recruiting for high-risk mRCC clinical trials and possible overestimation of the benefits of new treatment regimens

    loading  Loading Related Articles